Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon

TY - JOUR

T1 - Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon

AU - Belch, J. J. F.

AU - Shaw, B.

AU - Sturrock, R. D.

AU - Madhok, R.

AU - Leiberman, P.

AU - Forbes, C. D.

PY - 1985

Y1 - 1985

N2 - CL115,347 (Cyanamid International) is a stable transdermally absorbed prostaglandin E2 analogue said to have an antiplatelet vasodilatory effect. In a trial of this drug in Raynaud's phenomenon 15 patients were given 1 mg CL115,347/day transdermally for 6 weeks and 14 were given a placebo. The treated group had fewer and shorter spasm attacks and better healing of ulcers as assessed on a visual analogue scale. Blood supply as measured by cold challenge plethysmography ('Medimatic SP2') was also improved by CL115,347, as were hand temperatures. The treated group also had a significant rise in platelet count, but initial decreases in platelet aggregation were not maintained up to the end of the study.

AB - CL115,347 (Cyanamid International) is a stable transdermally absorbed prostaglandin E2 analogue said to have an antiplatelet vasodilatory effect. In a trial of this drug in Raynaud's phenomenon 15 patients were given 1 mg CL115,347/day transdermally for 6 weeks and 14 were given a placebo. The treated group had fewer and shorter spasm attacks and better healing of ulcers as assessed on a visual analogue scale. Blood supply as measured by cold challenge plethysmography ('Medimatic SP2') was also improved by CL115,347, as were hand temperatures. The treated group also had a significant rise in platelet count, but initial decreases in platelet aggregation were not maintained up to the end of the study.

U2 - 10.1016/S0140-6736(85)92862-4

DO - 10.1016/S0140-6736(85)92862-4

M3 - Article

C2 - 2860386

SN - 0140-6736

VL - 1

SP - 1180

EP - 1183

JO - Lancet

JF - Lancet

IS - 8439

ER -